BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Larouche V, Akirov A, Alshehri S, Ezzat S. Management of Small Bowel Neuroendocrine Tumors. Cancers (Basel) 2019;11:E1395. [PMID: 31540509 DOI: 10.3390/cancers11091395] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Gonzáles-Yovera JG, Roseboom PJ, Concepción-Zavaleta M, Gutiérrez-Córdova I, Plasencia-Dueñas E, Quispe-Flores M, Ramos-Yataco A, Alcalde-Loyola C, Massucco-Revoredo F, Paz-Ibarra J, Concepción-Urteaga L. Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art. World J Methodol 2022; 12(5): 381-391 [DOI: 10.5662/wjm.v12.i5.381] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Fu X, Wei S, Wang T, Fan H, Zhang Y, Costa CD, Brandner S, Yang G, Pan Y, He Y, Li N. Research Status of the Orphan G Protein Coupled Receptor 158 and Future Perspectives. Cells 2022;11:1334. [DOI: 10.3390/cells11081334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hajjar R, Mercier F, Passot G, Pasquer A, Gelli M, Levine EA, Villeneuve L, Poncet G, Walter T, Glehen O. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.03.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kalligeros M, Diamantopoulos L, Toumpanakis C. Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review. Biology (Basel) 2021;10:950. [PMID: 34681049 DOI: 10.3390/biology10100950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Mazlom H, Teuwen LA, Peeters M. Management of small bowel adenocarcinoma: making the most of the available evidence to inform routine practice. Curr Opin Oncol 2021;33:368-71. [PMID: 33882527 DOI: 10.1097/CCO.0000000000000747] [Reference Citation Analysis]
6 Dawod M, Gordoa TA, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel M, Lamarca A. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Curr Treat Options Oncol 2021;22:73. [PMID: 34185197 DOI: 10.1007/s11864-021-00863-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Fehrenbach U, Xin S, Hartenstein A, Auer TA, Dräger F, Froböse K, Jann H, Mogl M, Amthauer H, Geisel D, Denecke T, Wiedenmann B, Penzkofer T. Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI-A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making. Cancers (Basel) 2021;13:2726. [PMID: 34072865 DOI: 10.3390/cancers13112726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Kipnis ST, Hung M, Kumar S, Heckert JM, Lee H, Bennett B, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Eads JR, Katona BW. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. JAMA Netw Open 2021;4:e212274. [PMID: 33755166 DOI: 10.1001/jamanetworkopen.2021.2274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ye X, Wang L, Xing Y, Song C. Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases. BMC Gastroenterol 2020;20:342. [PMID: 33059631 DOI: 10.1186/s12876-020-01487-6] [Reference Citation Analysis]
10 Levy S, van Veenendaal LM, Korse CM, Breekveldt ECH, Verbeek WHM, Vriens MR, Kuhlmann KFD, van den Berg JG, Valk GD, Tesselaar MET. Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival. J Clin Med 2020;9:E2502. [PMID: 32756529 DOI: 10.3390/jcm9082502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
11 Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat 2020;53:100715. [PMID: 32679188 DOI: 10.1016/j.drup.2020.100715] [Cited by in Crossref: 116] [Cited by in F6Publishing: 131] [Article Influence: 38.7] [Reference Citation Analysis]
12 Kántás B, Börzsei R, Szőke É, Bánhegyi P, Horváth Á, Hunyady Á, Borbély É, Hetényi C, Pintér E, Helyes Z. Novel Drug-Like Somatostatin Receptor 4 Agonists are Potential Analgesics for Neuropathic Pain. Int J Mol Sci 2019;20:E6245. [PMID: 31835716 DOI: 10.3390/ijms20246245] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
13 Vadera S, Thomas D. Small bowel carcinoid tumour. Radiopaedia.org 2017. [DOI: 10.53347/rid-56226] [Reference Citation Analysis]